Peramivir (trihydrate)

• CAS Number:

  1041434-82-5

• UNSPSC Description:

  Peramivir trihydrate (RWJ-270201 trihydrate) is a highly potent, selective and orally active influenza virus neuraminidase (NA) inhibitor, with IC50 values ranging from 0.9 to 4.3 nM for nine NA subtypes[1][2][3].

• Target Antigen:

  ERK; IKK; Influenza Virus; JNK; p38 MAPK; STAT

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;JAK/STAT Signaling;MAPK/ERK Pathway;NF-κB;Stem Cell/Wnt

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Peramivir-trihydrate.html

• Solubility:

  DMSO : < 1 mg/mL (ultrasonic)|H2O : 5 mg/mL (ultrasonic)

• Smiles:

  O[C@H]1[C@]([C@H](C(CC)CC)NC(C)=O)([H])[C@H](NC(N)=N)C[C@@H]1C(O)=O.[H]O.[H]O.[H]O

• Molecular Weight:

  382.45

• References & Citations:

  [1]Zhang C, et al. Peramivir, an anti-influenza virus drug, exhibits potential anti-cytokine storm effects [J]. Frontiers in Immunology, 2022, 13: 856327.|[2]Pascua P N Q, et al. Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection [J]. Scientific reports, 2017, 7(1): 7345.|[3]Alame M M, et al.. Peramivir: a novel intravenous neuraminidase inhibitor for treatment of acute influenza infections [J]. Frontiers in microbiology, 2016, 7: 450.Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00222-20.|PLoS One. 2018 Jul 12;13(7):e0200761. |Chemosphere. 2017 Feb;169:550-557.|Int Immunopharmacol. 2023 Jan 11;115:109706.|Int J Infect Dis. 2024 Jun 27:107134.|Nat Commun. 2013;4:2854.|PLoS One. 2015 Jun 25;10(6):e0131412.|PLoS Pathog. 2024 Feb 14;20(2):e1011981.|Sci Rep. 2021 Aug 11;11(1):16293.|University of Glasgow. School of Cancer Sciences.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched